VERA Latest Press Releases

-- October 2, 2026 --

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 Globe Newswire 9:24 AM

-- September 15, 2026 --

Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy Globe Newswire 6:30 AM

-- September 4, 2026 --

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 1, 2026 --

Vera Therapeutics to Participate at Upcoming Investor Conferences Globe Newswire 7:30 AM

-- August 10, 2026 --

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results Globe Newswire 4:05 PM

-- August 7, 2026 --

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 10, 2026 --

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 9, 2026 --

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner Globe Newswire 8:00 AM

-- July 7, 2026 --

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy Globe Newswire 12:37 PM

-- June 5, 2026 --

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 2, 2026 --

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes